1268327c-805e-4f52-b9ab-451f17e3d129
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.300
- E2F_TARGETS+0.300
- FATTY_ACID_METABOLISM+0.300
- MTORC1_SIGNALING+0.300
- PI3K_AKT_MTOR_SIGNALING+0.300
- PROTEIN_SECRETION+0.300
- ANDROGEN_RESPONSE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- KRAS_SIGNALING_DN+0.200
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- MYC_TARGETS_V2-0.200
- MYOGENESIS-0.200
- NOTCH_SIGNALING-0.200
- UV_RESPONSE_DN-0.200
- HYPOXIA-0.100
- KRAS_SIGNALING_UP-0.100
- TGF_BETA_SIGNALING-0.100
- ALLOGRAFT_REJECTION+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168535 | — | — | 0.672 |
| 2 | SRR2932839 | — | — | 0.667 |
| 3 | TCGA-AO-A0JD-01A-11R-A056-07 | — | C | 0.652 |
| 4 | SRR13311180 | — | — | 0.649 |
| 5 | TCGA-FD-A6TE-01A-12R-A33J-07 | — | — | 0.640 |
| 6 | SRR22247244 | — | cohortSC | 0.637 |
| 7 | MBCProject_2741_T1A_RNA | — | C | 0.626 |
| 8 | SRR27320672 | — | — | 0.610 |
| 9 | TCGA-A8-A09W-01A-11R-A00Z-07 | — | B | 0.609 |
| 10 | SRR1797278 | — | cohortSC | 0.607 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |